Author:
Wang Na,Yang Teng,Feng Xiuli,Wang Guofeng,Liujing
Reference42 articles.
1. Possible long-term efficacy of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes(SPIDDM) in the stage of non-insulin-dependency: an open-label randomized controlled pilot trial(SPAN-S);Awata;Diabetes Ther.,2017
2. Clinical observation of saxagliptin combined with insulin glargine in the treatment of adult ocessive autoimmune diabetes mellitus [J];Chao;J. Clin. Med. Eng.,2017
3. Effects of Sitagliptin on CD4+ and CD8+T lymphocytes in adult patients with occult autoimmune diabetes mellitus [J];Chen Jiawei;Zhejiang J. Integ. Trad. West. Med.,2017
4. Mapping of type 1 diabetes mellitus;Desai;Curr. Diabetes Rev.,2020
5. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes;Farngren;J. Clin. Endocrinol. Metab.,2012